more superbugs

Following on the last blog on colistin-resistant E coli, Paul Susman sent me the link http://www.coha.org/super-bacteria-in-rio-de-janeiros-olympic-arenas/  on the increasing spread of  Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria​, which has been around for many years. A 2011 article (Arnold RS, South Med J 2011; 104: 45) noted at that time that this difficult-to-treat organism, associated with significant morbidity and mortality, had already spread from the northeastern US to most of the world.  The CDC commented that 50% of patients infected with this organism will die from it. The current link references the upcoming Olympics in Brazil, noting:​

--KPC is found off the beaches in Rio, where rowing, canoeing and swimming events will take place (ie, the swimmers, sailors and rowers will be exposed). The source is likely sewage contamination of the waterways
--10 samples were taken from five different beaches (Copacabana, Ipanema, Leblon, Botafogo, and Flamengo) and all tested positive for KPC
    --Copababana is the site of the triathlon and open swimming competitions, tested positive in 10% of the samples
    --Botafogo, where sailing and canoeing events are to be held, had 100% of samples positive
    --Ipanema and Leblon, popular tourist beaches, had 50 and 60% of samples positive
    --Flamengo beach, where sailing competitions will be held, 90% tested positive
--another study found that Guanabara Bay was contaminated, likely because waste from thousands of households and hospitals that dump into the streams and rivers that empty there. They note that "at least 50% of the untreated sewage from Rio de Janeiro is dumped in to Guanabara Bay.
--KPC has been found there since 2010. the authorities promised the water would be cleaned. but alas....

--another article on Brazil highlights the high rates of methicillin-resistant Staph, vancomycin resistant Enterococci, b-lactamase resistant Klebsiella and E coli, and KPC (see Rossi F. Clinical Infectious Diseases 2011; 9: 1138). They attribute the resistance to: overuse of superantibiotics (eg colistin in the ICUs), high total consumption of antibiotics, availability of over-the-counter antibiotics, inadequate dosing of antibiotics, and poor adherence. 
--also Brazil is the world's largest beef exporter with the world's largest commercial cattle herd. The government does regulate antibiotic use (as opposed to the US), though antimicrobial resistance has been found in Brazilian cattle

Commentary:
--I guess there is more concern about the Olympics than Zika...
--I don't mean to single out Brazil by this example. But this example yet again reinforces the big picture of potential outbreaks of untreatable infections caused by antibiotic resistance in common microbes. This is a worldwide phenomenon and really does need to be approached in a coherent worldwide manner

--see http://blogs.bmj.com/ebm/category/antimicrobial-resistance/ for a large number of blogs on this issue, including the US White House special report (see http://blogs.bmj.com/ebm/2015/04/08/primary-care-corner-with-geoffrey-modest-md-us-effort-to-combat-antibiotic-resistant-bacteria/ ),  as well as the WHO report on antimicrobialresistance (see  http://blogs.bmj.com/ebm/2014/07/11/primary-care-corner-with-geoffrey-modest-md-whos-remarkable-scary-report/​ which documents the remarkably (and scary) presence of really bad resistant microbes all around the world


geoff

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure -- i believe these trials (not cited specifically by the FDA) were the ones in the blog
Read more

cystatin c: better predictor of bad outcomes than creatinine

Image
  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr  <15 -- mean urinary albumin-to-creat ratio: 12 mg/g -- comorbidities: hypertension 59%, diabetes 8%, coronary heart di
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardi
Read more